In this study, we investigated the effect of ULBP2, a ligand for NKG2D, on the efficacy of CD4+CD25+ T cell-targeted immunotherapies using a CT26 mouse colon cancer model engineered to ectopically express ULBP2. Here, ULBP2 is linked to malignant colon neoplasm.